VOR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.974

-88.93%

-1.563

-69.95%

-1.587

-99.37%

Estimates Revision

Stock Price

Go Down

-59.71%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast VOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VOR is 40.00 USD with a low forecast of 9.00 USD and a high forecast of 64.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

9.00

Averages

40.00

High

64.00

Current: 0.000

Low

9.00

Averages

40.00

High

64.00

Baird

Outperform -> NULL

downgrade

$64 -> $46

2025-12-23

Reason

Baird

Price Target

$64 -> $46

2025-12-23

downgrade

Outperform -> NULL

Reason

Baird lowered the firm's price target on Vor Bio to $46 from $64 and keeps an Outperform rating on the shares. The firm updated its model.

JPMorgan

Anupam Rama

Overweight -> Overweight

downgrade

$43 -> $40

2025-12-19

Reason

JPMorgan

Anupam Rama

Price Target

$43 -> $40

2025-12-19

downgrade

Overweight -> Overweight

Reason

JPMorgan analyst Anupam Rama lowered the firm's price target on Vor Bio to $40 from $43 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.

TD Cowen

initiated

2025-12-17

Reason

TD Cowen

Price Target

2025-12-17

initiated

Reason

TD Cowen initiated coverage of Vor Bio with a Buy rating and no price target. The firm cites telitacicept's "promising" mechanism of action, "differentiated strong data," and potential across several indications for the Buy rating.

JPMorgan

Overweight

initiated

$43

2025-12-09

Reason

JPMorgan

Price Target

$43

2025-12-09

initiated

Overweight

Reason

JPMorgan initiated coverage of Vor Bio with an Overweight rating and $43 price target. The firm sees the company's telitacicept as "highly de-risked" across a range of indications. Vor is focusing on global indications that are less competitive but still have significant unmet need, the analyst tells investors in a research note. JPMorgan sees a "significant valuation disconnect" in the shares based on the probability-adjusted value of telitacicept in myasthenia gravis and primary Sjogren's disease alone.

Wedbush

Martin Fan

Neutral

initiated

2025-11-25

Reason

Wedbush

Martin Fan

Price Target

2025-11-25

initiated

Neutral

Reason

Wedbush analyst Martin Fan assumed coverage of Vor Bio with a Neutral rating with a price target of $9, up from 40c. The firm notes Vor's lead candidate telitacicept is a BAFF/APRIL ligand trap approved in China for systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis. Wedbush sees read-through to all development indications should telitacicept yield comparable efficacy to leading MG and SjD candidates in global trials. However, considering the company's reliance on a single asset and a long timeline before first data outside of China, the firm recommends investors remain on the sidelines until global MG data emerge in 2027.

H.C. Wainwright

Buy

downgrade

$55 -> $32

2025-11-14

Reason

H.C. Wainwright

Price Target

$55 -> $32

2025-11-14

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Vor Bio to $32 from $55 and keeps a Buy rating on the shares. The firm cites share dilution from the capital raise and adjustments to reflect the company's opportunity in Sjogren's disease for the target cut.

Valuation Metrics

The current forward P/E ratio for Vor Biopharma Inc (VOR.O) is -1.98, compared to its 5-year average forward P/E of -3.31. For a more detailed relative valuation and DCF analysis to assess Vor Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.31

Current PE

-1.98

Overvalued PE

0.50

Undervalued PE

-7.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.53

Current EV/EBITDA

-1.31

Overvalued EV/EBITDA

2.30

Undervalued EV/EBITDA

-5.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 549.93% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 549.93% over the last month.

Sold

Bought

VOR News & Events

Events Timeline

No data

News

5.0

2025-12-23Globenewswire

Vor Biopharma Appoints Two New Board Members to Support $150M PIPE Financing

8.5

2025-12-15Newsfilter

Vor Bio Secures $150 Million in Private Placement at $10.81 per Share

4.0

2025-12-09SeekingAlpha

J.P. Morgan Initiates Coverage on Lead Asset with Overweight Rating, Boosting Bio Shares

People Also Watch

Frequently Asked Questions

What is Vor Biopharma Inc (VOR) stock price today?

The current price of VOR is 12.78 USD — it has decreased -5.75 % in the last trading day.

What is Vor Biopharma Inc (VOR)'s business?

Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

What is the price predicton of VOR Stock?

What is Vor Biopharma Inc (VOR)'s revenue for the last quarter?

Vor Biopharma Inc revenue for the last quarter amounts to -28.11M USD, decreased -1.42 % YoY.

What is Vor Biopharma Inc (VOR)'s earnings per share (EPS) for the last quarter?

Vor Biopharma Inc. EPS for the last quarter amounts to -53906000.00 USD, increased 131.17 % YoY.

What changes have occurred in the market's expectations for Vor Biopharma Inc (VOR)'s fundamentals?

The market is revising No Change the revenue expectations for VOR for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -59.71%.

How many employees does Vor Biopharma Inc (VOR). have?

Vor Biopharma Inc (VOR) has 159 emplpoyees as of January 09 2026.

What is Vor Biopharma Inc (VOR) market cap?

Today VOR has the market capitalization of 280.02M USD.